NCT07042295
Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 103 versions: 28 with changes below, 22 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 57 → 60 locations
- Minor Study sites: 58 to 59
- Minor Trial sites expanded: 54 → 57 locations
- Minor Study sites: 55 to 57
- Minor Site details revised at 1 of 55 sites
- Minor Study sites: 54 to 55
Notable Recruitment resumed after suspension Show 4 more changesShow less
- Eligibility criteria expanded, about 54 words
- Trial sites expanded: 51 → 54 locations
- Secondary endpoints: details revised at 1 of 6 entries
- Study description revised
- Stopped Recruitment suspended Sponsor's reason: Other - planned analysis of safety and efficacy data
- Site details revised at 51 of 51 sites
- Minor Trial sites expanded: 42 → 50 locationsv95
- Minor Study sites: 42 to 50v94
- Minor Study sites: 41 to 42v93
- Minor Trial sites expanded: 38 → 41 locationsv92
- Minor Study sites revised (38)v91
- Notable Eligibility criteria expanded, about 6 words
- Study description shortened, about 3 words
- Notable Trial status: Suspended to Recruiting
- Study sites: 32 to 38
- Minor Study sites revised (32)v87
- Stopped Recruitment suspended Sponsor's reason: Other - safety run-in for initial cohort of participants
- Site details revised at 32 of 32 sites
- Minor Study sites: 31 to 32v84
- Minor Study sites: 30 to 31v82
- Minor Study sites: 29 to 30v81
- Minor Study sites: 27 to 29v80
- Minor Trial sites expanded: 20 → 23 locationsv79
- Minor Trial sites expanded: 17 → 20 locationsv78
- Minor Study sites: 20 to 23v77
- Minor Study sites: 17 to 20v76
- Minor Trial sites expanded: 9 → 17 locationsv67
- Minor Start date changed from estimate of Oct 25, 2026 to Mar 23, 2026v64
- Minor Study sites: 8 to 9v59
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (6)
Show 1 moreShow less
Arms and interventions
Patients receive amivantamab and hyaluronidase SC over at least 5 minutes on days 1, 8, 15 and 22 of cycle 1 and day 1 of subsequent cycles. Cycles repeat every 28 days for 24 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection on study and CT scan and/or MRI throughout the study.
Patients receive cetuximab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days for 24 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection on study and CT and/or MRI throughout the study.
Drugs: Amivantamab and Recombinant Human Hyaluronidase
Procedures: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
Biologicals: Cetuximab
Sites
60 sites in 1 country